These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 15838331)

  • 21. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
    Pham I; Gonzalez W; el Amrani AI; Fournié-Zaluski MC; Philippe M; Laboulandine I; Roques BP; Michel JB
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1339-47. PubMed ID: 8389863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
    Ksander GM; Savage P; Trapani AJ; Balwierczak JL; Jeng AY
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S71-3. PubMed ID: 9595404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel therapy approach in primary stroke prevention: simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival.
    Wengenmayer C; Krikov M; Mueller S; Lucht K; Villringer A; Hocher B; Unger T; Thoene-Reineke C
    Neurol Res; 2011 Mar; 33(2):201-7. PubMed ID: 21801596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats.
    Trapani AJ; Beil ME; Bruseo CW; De Lombaert S; Jeng AY
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S40-3. PubMed ID: 11078331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner.
    Kalk P; Sharkovska Y; Kashina E; von Websky K; Relle K; Pfab T; Alter M; Guillaume P; Provost D; Hoffmann K; Fischer Y; Hocher B
    Hypertension; 2011 Apr; 57(4):755-63. PubMed ID: 21339476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.
    Jullien N; Makritis A; Georgiadis D; Beau F; Yiotakis A; Dive V
    J Med Chem; 2010 Jan; 53(1):208-20. PubMed ID: 19899765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats.
    Intengan HD; Schiffrin EL
    Hypertension; 2000 Jun; 35(6):1221-5. PubMed ID: 10856267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of thromboxane synthetase potentiates the antihypertensive action of an angiotensin-converting enzyme inhibitor by a prostaglandin-dependent but kinin-independent mechanism.
    Levens NR; Cóte D; Ksander G
    J Pharmacol Exp Ther; 1991 Oct; 259(1):219-27. PubMed ID: 1920118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic vasopeptidase inhibition restores endothelin-converting enzyme activity and normalizes endothelin levels in salt-induced hypertension.
    Quaschning T; d'Uscio LV; Shaw S; Viswambharan H; Ruschitzka FT; Lüscher TF
    Nephrol Dial Transplant; 2001 Jun; 16(6):1176-82. PubMed ID: 11390717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats.
    Pu Q; Touyz RM; Schiffrin EL
    J Hypertens; 2002 May; 20(5):899-907. PubMed ID: 12011651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
    Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ
    Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
    Mifsud SA; Burrell LM; Kubota E; Jaworski K; Cooper ME; Wilkinson-Berka JL
    Clin Exp Hypertens; 2004 Jan; 26(1):69-80. PubMed ID: 15000298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat.
    Dai ZK; Hsieh CC; Chai CY; Wu JR; Jeng AY; Chou SH; Wu BN; Yeh JL; Chen IJ; Tan MS
    Pediatr Pulmonol; 2010 Nov; 45(11):1076-85. PubMed ID: 20658482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
    Trapani AJ; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Jeng AY
    Life Sci; 2000; 67(9):1025-33. PubMed ID: 10954036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats.
    Webb RL; Navarrete AE; Davis S; de Gasparo M
    J Hypertens; 1998 Jun; 16(6):843-52. PubMed ID: 9663925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats.
    Pu Q; Amiri F; Gannon P; Schiffrin EL
    J Hypertens; 2005 Feb; 23(2):401-9. PubMed ID: 15662229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats.
    McMahon EG; Palomo MA; Brown MA; Bertenshaw SR; Carter JS
    Am J Hypertens; 1993 Aug; 6(8):667-73. PubMed ID: 8217029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
    Daull P; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.
    Trapani AJ; Beil ME; Bruseo CW; Fink CA; Hoyer D; Savage P; Jeng AY
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():102S-106S. PubMed ID: 12193065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.